The title of this post is the headline of our latest column for LabTimes. It’s inspired by a number of animated discussions on Retraction Watch following our coverage of various Western blot problems — some unintentional, and some, well, less so.
Take, for example, this comment, which we quote in the column: Continue reading Can we trust Western blots?
A group of French cardiology researchers have retracted a study of a potential way to rule out heart attacks, after it became clear they had used data from another study without alerting the journal.
In an unusually forthright letter accompanying the retraction of “Concomitant measurement of copeptin and high-sensitivity troponin for fast and reliable rule out of acute myocardial infarction,” originally published in Intensive Care Medicine, Bruno Riou and colleagues note: Continue reading Salami slicing and heart attacks don’t mix: Duplication, lack of transparency lead to retraction
A partial retraction has joined the ten retractions and five corrections of Anil Potti’s papers, this one of a 2008 paper in Molecular Cancer Therapeutics. The move comes 14 months after the retraction of the Nature Medicine paper upon which much of the Molecular Cancer Therapeutics paper was based.
Here’s the notice: Continue reading A “retraction in part” for Anil Potti and colleagues, in Molecular Cancer Therapeutics
In 2010, a group of crystallographers immunologists and allergy researchers at the University of Salzburg published a paper in the Journal of Immunology claiming to have derived the structure of a birch pollen allergen.
That structure, however, caught the attention of Bernhard Rupp, an eminent crystallographer. In January of this year, Rupp submitted a paper to Acta Crystallographica Section F pointing out problems with it, which prompted the editors of the crystallography journal to contact the authors of the original paper a month later. Those authors, it turns out, agreed with Rupp, they write in a response to his paper published in the April 2012 issue of Acta Crystallographica Section F: Continue reading Protein structure retracted after investigation into “highly improbable features,” journal calls it fraud
After five years of operation, the Nature Publishing Group is will no longer accept submissions to its preprint server Nature Precedings, having found the experiment “unsustainable as it was originally conceived.”
Here’s the announcement sent to all Nature Precedings registrants this morning: Continue reading Nature Precedings to stop accepting submissions next week after finding model “unsustainable”
The retraction count for Dipak Das, the resveratrol researcher whom the University of Connecticut found to have committed 145 counts of fabrication and falsification of data, has risen to eight with withdrawals by Free Radical Biology & Medicine and Free Radical Research.
The two Free Radical Biology & Medicine retractions, for “Expression of the longevity proteins by both red and white wines and their cardioprotective components, resveratrol, tyrosol, and hydroxytyrosol” (cited 38 times, according to Thomson Scientific’s Web of Knowledge) and “Redox regulation of resveratrol-mediated switching of death signal into survival signal” (cited 32 times), are carefully detailed and read the same way: Continue reading Three more retractions for resveratrol researcher Dipak Das, in free radical journals
We have an update in the case of two Japanese scientists who first came to our attention when they retracted a 13-year-old paper in the Journal of Neuroscience last year. Shortly after that, we learned, thanks to a report in Sankei Shimbun and a helpful Retraction Watch reader, that some 17 papers were being investigated.
It now appears that 19 papers by the two researchers, Kenji Okajima and Naoki Harada, ended up under scrutiny.
Nagoya City University said last week that their investigation had concluded that Okajima and Harada committed misconduct. The university dismissed Harada, whom they found guilty of misconduct in at least eight of the papers. The investigation couldn’t find any evidence that Okajima was directly involved, but suspended him for six months because he supervised the work. Continue reading Japanese universities find pair of researchers guilty of misconduct in 19 papers
If you’re a rabbit and you haven’t figured out where to carry your cell phone, your front pocket is just fine.
That’s what you could reasonably infer from the retraction of a paper in the International Journal of Andrology purporting to show that mobile phones affected rabbits’ sperm counts. The notice, signed by the journal’s editor, Ewa Rajpert-De Meyts (we added links): Continue reading Rabbits needn’t worry about cell phones’ effects on their sperm count, say three retractions
On Tuesday, we covered a retraction in the Proceedings of the National Academy of Sciences (PNAS) involving zalutumumab, a compound once being developed for treatments of head and neck cancer. As we noted at the time, the authors decided to retract the paper because they no longer trusted the method they used. One of the authors didn’t sign the notice, and we’ve now heard from her about why.
First, a comment from lead author Paul W.H.I Parren, who tells Retraction Watch: Continue reading PNAS author explains why she didn’t sign retraction notice for potential anti-cancer drug study
There’s another non-unanimous retraction in the Proceedings of the National Academy of Sciences (PNAS) this week, and this one involves an anti-tumor antibody that may not be what the authors originally thought it was.
According to the notice for “The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility:” Continue reading Another non-unanimous PNAS retraction, for potential anti-cancer drug, after company’s method proves unreliable